The U.S. FDA approved LONSURF® (trifluridine and tipiracil) for the treatment of patients with refractory metastatic colorectal cancer (mCRC) who are no longer responding two other therapies.  LONSURF is manufactured by Taiho Oncology Inc., a pharmaceutical company based in Princeton, NY and a subsidiary of Otsuka Holdings Co., a Japanese pharmaceutical company headquartered in Yokyo, Osaka and Naruto, Japan.  LONSURF is an oral medication containing two active ingredients, trifluridine and tipiracil.  The FDA approval is based on results from the global Phase III RECOURSE trial that has demonstrated improved overall survival in mCRC patients who have been previously treated with other therapies.  This approval offers another option to treat patients with mCRC, whose disease has progressed after standard treatment and have had limited options.

 

Original Article:

https://www.taihooncology.com/us/newsroom/press-releases/Taiho-Oncology-Inc-Announces-FDA-Approval-of-LONSURF-for-Refractory-Metastatic-Colorectal-Cancer